Skip to main content
main-content
Top

06-03-2017 | Systemic lupus erythematosus | Review | Article

Novel Treatments in Lupus

Journal:
Current Rheumatology Reports

Author: Vasileios C. Kyttaris

Publisher: Springer US

Abstract

The treatment of systemic lupus erythematosus (SLE) still depends on non-specific immunosuppression. Herein, we review promising targeted therapies that have the potential to change this therapeutic paradigm.
Besides the FDA-approved B lymphocyte stimulator (BLyS) inhibitor, belimumab, interferon-α represents a promising treatment target, albeit with modest effectiveness primarily in non-renal SLE. Preclinical and early-phase clinical trials using biologics and small molecules targeting B and T cell activation as well as the cross-talk between these cells also show promise.
BLyS and interferon targeting show the most promising results in challenging the current treatment status in non-renal SLE.

Please log in to get access to this content

Related topics